Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06998771 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Name: JSKN003 Combined Treatment of HER2-positive Gastric Cancer — clinical trial record (NCT06998771)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorShanghai JMT-Bio Inc.

Started2025-06-15

View on ClinicalTrials.gov ↗

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Gastric Cancer

1,194 trials monitored

See 60 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.

Trial Details

NCT Number	NCT06998771
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	HER2-positive Gastric Cancer
Enrollment	153 participants
Start Date	2025-06-15
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-31